• IAM LC vs LEKC for Pulmonary Permeability

  2026-09-11

  This 2024 Journal of Chromatography A study provides a direct comparison of immobilised artificial membrane liquid chromatography (IAM LC) and liposome electrokinetic capillary chromatography (LEKC) for modelling drug–membrane partitioning and pulmonary permeability. Across 26 drug-like molecules, LEKC showed stronger relationships with apparent lung permeability, whereas IAM LC offered broader compound coverage and simpler high-throughput implementation.

• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-09-11

  The reference study introduces a phenotype-first strategy for reducing SPP1 expression in tumor-associated macrophages using small-molecule screening and a TAM-avid CANDI nanoconstruct. Its lead formulation, CANDI460, lowered SPP1 in cellular and mouse models and produced tumor remissions, supporting SPP1-high myeloid cells as a therapeutically actionable compartment.

• Hydroxytyrosol N2302 for Reliable Cell Assays

  2026-09-10

  This scenario-driven guide explains how Hydroxytyrosol (SKU N2302) can be incorporated into cell viability, proliferation, cytotoxicity, and oxidative-stress workflows without confusing antioxidant activity with cell survival. It combines formulation data, assay controls, protocol starting points, interpretation safeguards, and practical vendor-selection criteria for biomedical laboratories.

• Obeticholic Acid Workflows for FXR Liver Research

  2026-09-10

  Obeticholic Acid provides a receptor-proximal way to connect FXR activation with bile acid transport, metabolic signaling, and fibrosis-related phenotypes. This practical guide translates a recent 11β-HSD1 liver fibrosis study into complementary hepatocyte, immune, and in vivo workflows while emphasizing controls and troubleshooting.

• Olsalazine Sodium: From Chemotaxis to Translation

  2026-09-09

  A translational perspective on Olsalazine Sodium as a mesalamine dimer, anti-inflammatory prodrug, and research tool spanning LTB4 chemotaxis, colorectal cancer tumor models, and xenobiotic transport studies.

• Prochlorperazine Hemidystonia as a Stroke Mimic

  2026-09-09

  The reference case shows how prochlorperazine-induced hemidystonia can closely resemble acute ischemic stroke, especially when unilateral weakness and dysarthria trigger an emergency stroke response. Its practical contribution is a medication-centered, serial examination strategy that helps clinicians identify a reversible stroke mimic without delaying appropriate neuroimaging or safety assessment.

• Rimonabant (SR141716): A Translational CB1 Lens

  2026-09-08

  Rimonabant (SR141716) is more than a historical appetite-focused compound: it is a selective CB1 pharmacology tool for separating endocannabinoid signaling from emerging non-cannabinoid mechanisms. By pairing CB1 antagonism with the A2A-dependent terpene findings reported in chronic pain research, translational teams can design sharper experiments across appetite, inflammation, neurobiology, and pain.

• Isoliensinine, TRPV1–AMPK in MAFLD Fibrosis

  2026-09-08

  A 2025 Journal of Future Foods study identifies a TRPV1–AMPK/ACC–lipid droplet axis through which isoliensinine reduces hepatic stellate cell activation and fibrosis in MAFLD models. Its combination of dietary and chemical in vivo models with LX2-cell mechanistic experiments provides a framework for testing lipid droplet restoration as an anti-fibrotic strategy, while leaving human translation and pathway specificity for further study.

• Chloroquine BA1002: Practical Research Workflow

  2026-09-07

  Chloroquine (BA1002) provides a solvent-aware, assay-focused approach for investigating lysosomal function, autophagy-related readouts, inflammatory signaling, and selected cancer or antiviral models. It should be treated as a pleiotropic research compound rather than a selective pathway probe or clinical dosing substitute, particularly when no directly matched paper evidence is available.

• Chloroquine as a Probe of Itch–Pain Circuits

  2026-09-07

  Chloroquine is more than an autophagy inhibitor: its activity at MrgprA3+ sensory neurons creates a valuable framework for separating itch, pain, inflammation, and cellular stress in translational assays.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-09-05

  The reference study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through Gαq/11, Gα12/13, Rho GTPases, and the SLK/LOK kinase module. This signaling axis links receptor activity to triple-negative breast cancer motility, invasion, and metastatic colonization, providing a mechanistic framework for studying GPCR-driven cytoskeletal plasticity.

• Demethyleneberberine: Assay Design and Mechanism

  2026-09-04

  Demethyleneberberine (DMB) is a mechanism-rich natural alkaloid for NSCLC and inflammatory disease research. This guide focuses on choosing orthogonal assays that distinguish cytostasis, senescence, and anti-inflammatory activity while preserving model-specific interpretation.

• Deracoxib and Piroxicam in Canine Osteosarcoma

  2026-09-04

  The reference study compared Deracoxib and piroxicam directly in three canine osteosarcoma cell lines and a fibroblast model, showing stronger and more consistent growth inhibition with Deracoxib. Its findings support selective in vitro cytotoxicity at intermediate-to-high concentrations, but the absence of DNA fragmentation and limited apoptosis testing argue against assuming a specific cell-death mechanism.

• PDK4 Inhibitors for Metabolic Disease: Study Insights

  2026-09-03

  This 2019 Journal of Medicinal Chemistry study used anthraquinone-based medicinal chemistry and allosteric-site modeling to identify compound 8c as a potent PDK4 inhibitor. The lead combined cellular and biochemical activity with metabolic, allergy, and cancer-related efficacy signals, while its stability and pharmacokinetic characterization supported further preclinical investigation.

• WY-14643 for PPARα and Metabolic Research

  2026-09-03

  WY-14643 (Pirinixic Acid) provides a direct pharmacologic handle for testing PPARα-dependent lipid metabolism, inflammation, and insulin sensitivity enhancement. Its use alongside multiomics and tumor-microenvironment assays can help distinguish receptor-driven effects from broader activity of endogenous fatty acids.

7829 records 1/522 page Next 12345 下5页 Last page